Glycosylated hemoglobin and hypoglycaemia in patients with type 2 diabetes mellitus: Technosphere insulin and usual antihyperglycaemic regimen vs usual antihyperglycaemic regimen

被引：0
|
作者：
Boss, A. H. [1 ]
Raskin, P. [2 ]
Phillips, M. [1 ]
Rossiter, A. [1 ]
Richardson, P. C. [1 ]
机构：
[1] MannKind Corp, Valencia, Spain
[2] Univ Texas SW Med Ctr Dallas, Dallas, TX USA
来源：
DIABETOLOGIA | 2010年 / 53卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
5
引用
收藏
页码：S8 / S9
页数：2
相关论文
共 50 条
  • [11] Efficacy and Tolerability of Pioglitazone in Patients with Type 2 Diabetes Mellitus Comparison with Other Oral Antihyperglycaemic Agents
    Derosa, Giuseppe
    DRUGS, 2010, 70 (15) : 1945 - 1961
  • [12] TIME TO INITIATION OF ORAL ANTIHYPERGLYCAEMIC AND STATIN THERAPY IN PATIENTS WITH NEWLY DIAGNOSED TYPE 2 DIABETES MELLITUS
    Tunceli, K.
    Sun, P.
    Seck, T.
    Ambegaonkar, B.
    Lento, K.
    Davies, M. J.
    Zhang, Q.
    Radican, L.
    VALUE IN HEALTH, 2011, 14 (07) : A387 - A387
  • [13] Underutilisation of antihyperglycaemic combination therapy in eligible, treatment-naive patients with type 2 diabetes mellitus
    Qiu, Y.
    Fu, A. Z.
    Davies, M. J.
    Engel, S. S.
    DIABETOLOGIA, 2012, 55 : S405 - S405
  • [14] Risk of any hypoglycaemia with newer antihyperglycaemic agents in patients with type 2 diabetes: A systematic review and meta-analysis
    Kamalinia, Sanaz
    Josse, Robert G.
    Donio, Patrick J.
    Leduc, Lindsay
    Shah, Baiju R.
    Tobe, Sheldon W.
    ENDOCRINOLOGY DIABETES & METABOLISM, 2020, 3 (01)
  • [15] Hypoglycaemia is reduced with use of inhaled Technosphere® Insulin relative to insulin aspart in type 1 diabetes mellitus
    Seaquist, E. R.
    Blonde, L.
    McGill, J. B.
    Heller, S. R.
    Kendall, D. M.
    Bumpass, J. B.
    Pompilio, F. M.
    Grant, M. L.
    DIABETIC MEDICINE, 2020, 37 (05) : 752 - 759
  • [16] CORRELATION OF GLYCOSYLATED HEMOGLOBIN AND BMI IN TYPE 2 DIABETES MELLITUS PATIENTS
    Rai, Narasimha K.
    JOURNAL OF EVOLUTION OF MEDICAL AND DENTAL SCIENCES-JEMDS, 2015, 4 (92): : 15739 - 15740
  • [17] Lipoprotein risk factors for cardiovascular disease in patients with type 2 diabetes mellitus treated with oral antihyperglycaemic agents
    Chu, JW
    Abbasi, F
    McLaughlin, TL
    Lamendola, C
    Schaaf, P
    Carlson, TH
    Leary, ET
    Reaven, GM
    DIABETES OBESITY & METABOLISM, 2003, 5 (05): : 333 - 337
  • [18] Influence of glucose, insulin fluctuation, and glycosylated hemoglobin on the outcome of sarcopenia in patients with type 2 diabetes mellitus
    Lin, Yuxi
    Zhang, Yongze
    Shen, Ximei
    Huang, Lingning
    Yan, Sunjie
    JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2021, 35 (06)
  • [19] Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus who were, or were not, on antihyperglycaemic agents at screening
    Gonzalez-Galvez, G.
    Jodar, E.
    Kim, K.
    Alba, M.
    Tong, C.
    Meininger, G.
    DIABETOLOGIA, 2014, 57 : S347 - S348
  • [20] Degree of control and delayed intensification of antihyperglycaemic treatment in type 2 diabetes mellitus patients in primary care in Spain
    Conthe, Pedro
    Mata, Manuel
    Orozco, Domingo
    Pajuelo, Francisco
    Sofia Barreto, Carmen
    Fernandez Anaya, Silvia
    Gomis, Ramon
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2011, 91 (01) : 108 - 114
12345